CSPC Pharmaceutical Group (HKG:1093) has obtained approval from China's National Medical Products Administration to conduct clinical trials of its Valsartan Levoamlodipine Maleate tablets in China, a Friday bourse filing said.
The drug is indicated for the treatment of primary mild and moderate hypertension that cannot be effectively controlled by monotherapy.
Shares of the pharmaceutical firm closed over 6% higher on Friday.
Price (HKD): $4.99, Change: $+0.30, Percent Change: +6.40%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.